


HEALTHCARE

Future Growth Opportunities in Generics

The impact of consolidation on market and competitive dynamics

By Revati Nehru

 Table of Contents

Revati Nehru

Revati Nehru is a healthcare analyst, with 3 years experience in healthcare marketing and market analysis in cancer and cardiovascular. During this time she has worked for multinational pharmaceutical companies and independent research houses. She is currently employed as a healthcare market analyst.

Copyright © 2006 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Future Growth Opportunities in Generics

Executive Summary	10	
Generics growth opportunities and branded defense strategies	10	
Generics market analysis by country and region	11	
Generics market analysis by therapeutic area	12	
Leading generics players	13	
Consolidation in the generics industry	14	
Chapter 1	Generics growth opportunities and branded defense strategies	16
Summary		16
Introduction		17
Key generics growth opportunities		17
Availability of off-patent treatments and paragraph IV challenges		20
Healthcare cost containment policies		22
The biogenerics/biosimilars opportunity		24
Mergers and acquisitions		25
Defense strategies from branded companies		26
Rx-to-OTC switching		26
Defensive pricing		27
Patent litigation		28
Reformulation		28
Authorized generics agreements and settlements		29
Launching in-house generics		30
Chapter 2	Generics market analysis by country and region	32
Summary		32
Introduction		33

Merck KGaA	Forecast sales	93
	Marketed product portfolio	94
Ivax	Forecast sales	95
	Marketed product portfolio	96
Apotex	Forecast sales	97
	Marketed product portfolio	98
Par	Forecast sales	99
	Marketed product portfolio	100
Alpharma	Forecast sales	101
	Marketed product portfolio	102
	Forecast sales	103

Chapter 5 Consolidation in the generics industry 106

Summary	106
Introduction	107
Factors influencing M&A deals across markets	107
Key deals in emerging markets	110
Dr. Reddy's	110
Betapharm acquisition	110
Roche's API facility acquisition	111
Trigenesis acquisition	111
Ranbaxy	112
Mundogen acquisition	112
Ethimed acquisition	112
Terapia acquisition	113
Egis	113
Serdix acquisition	114
Zentiva	114
Sicomed acquisition	114
Key deals in Western Europe	115
Sandoz/Novartis	115
Sabex acquisition	115
Hexal/Eon acquisition	116
Stada Arzneimittel	116
Hemofarm acquisition	117
Nizpharm acquisition	117
Other acquisitions	117
Ratiopharm	118
Magnafarma BV acquisition	118

	Pulmotec acquisition	118
	Ribosepharm acquisition	118
Merck KGaA		119
	Prasfarma acquisition	119
	NM Pharma acquisition	119
Actavis		120
	Alpharma acquisition	120
	Amide acquisition	120
	Sindan acquisition	121
	Keri Pharma acquisition	121
Key deals in the US		122
Watson		122
	Amarin acquisition	123
	Sekhsaria acquisition	123
	Andrx acquisition	123
Barr		124
	Pliva acquisition	124
Mylan		125
	Matrix Labs acquisition	125
Perrigo		126
	Agis acquisition	126
Other key deals		126
Teva		126
	Ivax acquisition	127
Conclusions		127
Chapter 6	Appendix	132
Glossary		132
Index		134

List of Figures

Figure 1.1:	Generics company growth strategies	18
Figure 1.2:	Number of ANDA and first-to-file approvals, 2001-2006	21
Figure 1.3:	Average monthly ANDA and first-to-file approvals, 2001-2006	22
Figure 1.4:	Pharmaceutical cost containment policies in developed and developing markets	23
Figure 2.5:	Market dynamics in the global unbranded generics market by country, 2004-05	37
Figure 3.6:	Market breakdown of the major therapy classes in the global unbranded generics market, 2001 & 2005	54
Figure 3.7:	Market dynamics of the major CNS unbranded generics, 2005	59
Figure 3.8:	Market dynamics of the major cardiovascular unbranded generics, 2005	63
Figure 3.9:	Market dynamics of the major alimentary tract and metabolism generics, 2005	66
Figure 3.10:	Market dynamics of the leading cancer unbranded generics, 2005	69
Figure 3.11:	Market dynamics of the leading anti-infectives unbranded generics, 2005	73
Figure 4.12:	Performance of major players in the global generics market, 2001 & 2005	81
Figure 5.13:	Factors shaping M&A deals across the US, EU and emerging markets	108
Figure 5.14:	Key generics M&A by region, 2004-06	109
Figure 5.15:	Competitive pressures influencing generics M&A strategies, 2005-06	128

List of Tables

Table 2.1:	Sales of unbranded generics by country, 2004-05	34
Table 2.2:	Sales of unbranded generics in North America, 2004-05	38
Table 2.3:	Sales of unbranded generics in Latin America, 2004-05	39
Table 2.4:	Sales of unbranded generics in major Western European markets, 2004-05	41
Table 2.5:	Sales of unbranded generics in major Central and Eastern European markets, 2004-05	42
Table 2.6:	Sales of unbranded generics in Japan, 2004-05	43
Table 2.7:	Sales of unbranded generics in China, 2004-05	45
Table 2.8:	Sales of unbranded generics in Asia-Pacific, 2001-05	46
Table 3.9:	Sales by major therapeutic area across the global unbranded generics market, 2004-05	52
Table 3.10:	Sales of major molecules in the global CNS unbranded generics market, 2004-05	55
Table 3.11:	Sales of major molecules in the global cardiovascular unbranded generics market, 2004-05	60
Table 3.12:	Sales of major molecules in the alimentary tract and metabolic disorders global unbranded generics market, 2004-05	64
Table 3.13:	Sales of major molecules in the global cancer unbranded generics market, 2004-05	67
Table 3.14:	Sales of major molecules in the global anti-infectives unbranded generics market, 2004-05	70
Table 3.15:	Forecast global unbranded generics sales by therapy area, 2005-11	74
Table 4.16:	Leading ten generics companies by global unbranded generics sales, 2004-05	80
Table 4.17:	Leading generics companies by global generics sales, 2004-05	83
Table 4.18:	Leading products in Novartis' generics portfolio, 2004-05	84

Table 4.19:	Forecast sales of Novartis' current generics portfolio, 2005-2011	86
Table 4.20:	Leading products in Teva's generics portfolio, 2004-05	86
Table 4.21:	Forecast sales of Teva's current generics portfolio, 2005-2011	87
Table 4.22:	Leading products in Mylan's generics portfolio, 2004-05	88
Table 4.23:	Forecast sales of Mylan's current generics portfolio, 2005-2011	90
Table 4.24:	Leading products in Ratiopharm's generics portfolio, 2004-05	90
Table 4.25:	Forecast sales of Ratiopharm's current generics portfolio, 2005-2011	91
Table 4.26:	Leading products in Watson's generics portfolio, 2004-05	92
Table 4.27:	Forecast sales of Watson's current generics portfolio, 2005-2011	93
Table 4.28:	Leading products in Merck KGaA's generics portfolio, 2004-05	94
Table 4.29:	Forecast sales of Merck KGaA's current generics portfolio, 2005-2011	95
Table 4.30:	Leading products in Ivax's generics portfolio, 2004-05	96
Table 4.31:	Forecast sales of Ivax's current generics portfolio, 2005-2011	97
Table 4.32:	Leading products in Apotex's generics portfolio, 2004-05	98
Table 4.33:	Forecast sales of Apotex's current generics portfolio, 2005-2011	99
Table 4.34:	Leading products in Par's generics portfolio, 2004-05	100
Table 4.35:	Forecast sales of Par's current generics portfolio, 2005-2011	101
Table 4.36:	Leading products in Alparma's generics portfolio, 2004-05	102
Table 4.37:	Forecast sales of Alparma's current generics portfolio, 2005-2011	103